Compare SYNA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | LIVN |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2002 | 1993 |
| Metric | SYNA | LIVN |
|---|---|---|
| Price | $86.27 | $66.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $100.78 | $67.38 |
| AVG Volume (30 Days) | ★ 892.9K | 629.6K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,144,400,000.00 | ★ $1,348,962,000.00 |
| Revenue This Year | $12.26 | $12.25 |
| Revenue Next Year | $10.86 | $6.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.35 | 8.63 |
| 52 Week Low | $41.80 | $32.48 |
| 52 Week High | $95.08 | $67.92 |
| Indicator | SYNA | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 61.24 |
| Support Level | $86.00 | $64.23 |
| Resistance Level | $95.08 | $67.20 |
| Average True Range (ATR) | 4.34 | 1.90 |
| MACD | -0.32 | 0.13 |
| Stochastic Oscillator | 36.87 | 76.42 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.